Adults 18 to 75, any sex, with Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Safety: Number of Participants With Major Bleeding EventsPrimary· Within 72 hours of initiation of r-tPA administration.
Major Bleeding as defined by International Society of Thrombosis and Hemostasis (ISTH), within 72 hours of initiation of r-tPA administration. Bleeding criteria are as follows: Major Bleeding in Non-Surgical Patients
1. Fatal bleeding; and/or
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome; and/or
3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more or leading to transfusion of two or more units of whole blood or red cells.
Group
Value
95% CI
BEC Treatment
1
Adverse events — posted to ClinicalTrials.gov
Time frame: From treatment through 30 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06433011 — The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
· NA
· not yet recruiting
NCT04248868 — tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
· Phase 3
· completed
Other recruiting trials for Pulmonary Embolism
Currently open trials in the same condition.
NCT07381712 — High-Flow Nasal Cannula Versus Non-Invasive Ventilation for Acute Respiratory Failure in Pulmonary Embolism.
· NA
· active not recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
· NA
· recruiting
NCT07003646 — Reperfusion Treatment in Acute Pulmonary Embolism
· recruiting
NCT06622876 — Incidental Discovery of Pulmonary Emboli Via CT Scan: Impact of Detections on Patient Care and Resulting Complications
· recruiting
Other Thrombolex, Inc. trials
Trials by the same sponsor.
NCT06433011 — The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
· NA
· not yet recruiting
NCT04248868 — tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thrombolex, Inc.
Last refreshed: 30 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927508.